Contact us

For more information about PERTZYE® (pancrelipase), prescription support services, or other product inquiries, contact a Chiesi CareDirect® Specialist.

Contact Chiesi CareDirect®

Mail:
Chiesi CareDirect
PO Box 30317
Bethesda, MD 20824-0317

Phone:
1-888-865-1222

Fax:
1-866-410-6241

Email:
chiesicaredirect@caremetx.com

Contact Chiesi, Inc.

Mail:
Chiesi, Inc.
1255 Crescent Green Drive
Suite 250
Cary, NC 27518

Phone:
1-888-466-6505

Request medical information

To request specific medical information about PERTZYE or to report adverse events or product complaints, contact the Medical Information Department.

Adverse events may also be reported to FDA’s MedWatch Program at 1-800-FDA-1088.

Mail:
Chiesi, Inc.
1255 Crescent Green Drive
Suite 250
Cary, NC 27518

Phone:
1-888-661-9260

Fax:
1-866-443-3092

Email:
US.Medical@chiesi.com

Important Safety Information

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PERTZYE exceed 2,500 lipase units/kg body weight per meal (or greater than 10,000 lipase units/kg body weight per day).

To avoid irritation of oral mucosa, do not chew PERTZYE or retain in the mouth.

Hyperuricemia may develop. Consider monitoring uric acid levels in patients with hyperuricemia, gout, or renal impairment.

There is theoretical risk of viral transmission with all pancreatic enzyme products including PERTZYE.

Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.

Most common adverse reactions (≥ 10%) are: diarrhea, dyspepsia, and cough.

Indication

PERTZYE® (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.

Please click here for Full Prescribing Information and Medication Guide.